Loading…
The data supports the therapeutic potential of TTX-MC138.
TransCode Therapeutics, Inc. (RNAZ) announced the publication of preclinical data supporting the therapeutic potential of its candidate, TTX-MC138, in Glioblastoma. The announcement was made following the publication in a peer-reviewed journal.
The published data demonstrated the efficacy and safety profile of TTX-MC138 in preclinical models of Glioblastoma, a type of aggressive brain cancer. The results indicate a significant reduction in tumor growth and improved survival rates in the treated groups.
As of the latest available data, TransCode Therapeutics has 832,420 shares in its free float.
This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.